US$ 24.01
is mounjaro glp 1 agonist GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 GLP-1 Agonist Therapy for Obesity
Description
One of the primary effects of Semaglutide GLP-1 is appetite suppression

2016;310:F1237

Wild-type (ECACC) and -arrestin-less HEK293 cells 41 stably expressing SNAP-GLP-1R were generated by G418 selection and maintained in DMEM at 25 mM d-glucose supplemented with 10% FBS and 1% penicillin/streptomycin

Stool that is consistently pale also suggests a lack of bile secretion, and the same recommendations for rapid weight loss would apply
If reactions are persistent or severe, consider changing injection sites more frequently or using a different formulation

It is helping some with my snacking issues
